mifepristone + placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Psychotic Depression

Conditions

Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis

Trial Timeline

Mar 1, 2008 → Jun 1, 2014

NCT ID

NCT00637494

About mifepristone + placebo

mifepristone + placebo is a phase 3 stage product being developed by Corcept Therapeutics for Psychotic Depression. The current trial status is terminated. This product is registered under clinical trial identifier NCT00637494. Target conditions include Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis.

What happened to similar drugs?

2 of 6 similar drugs in Psychotic Depression were approved

Approved (2) Terminated (3) Active (2)

❌quetiapineAstraZenecaPhase 3

🔄QuetiapineAstraZenecaPhase 3

❌QuetiapineAstraZenecaPhase 3

✅Asenapine 5-20 mg daily + Placebo 1-4 tablets dailyMerckApproved

✅Ziprasidone HCL (oral)PfizerApproved

🔄AripiprazoleBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05217758	Phase 2	Completed	Dec 9, 2021	Nov 12, 2024	Major Depressive Disorder
NCT00637494	Phase 3	Terminated	Mar 1, 2008	Jun 1, 2014	Psychotic Depression
NCT00146523	Phase 3	Completed	May 1, 2005	Jul 1, 2006	Major Depressive Disorder

Competing Products

14 competing products in Psychotic Depression

See all competitors

Product	Company	Stage	Hype Score
Olanzapine, Amantadine + Olanzapine and placebo	Eli Lilly	Phase 1	29
risperidone IR and LAI formulation	Johnson & Johnson	Phase 1	29
quetiapine	AstraZeneca	Phase 3	32
Quetiapine	AstraZeneca	Phase 3	40
Quetiapine	AstraZeneca	Phase 3	32
quetiapine + olanzapine + risperidone	AstraZeneca	Pre-clinical	26
Asenapine 5-20 mg daily + Placebo 1-4 tablets daily	Merck	Approved	43
Ziprasidone HCL (oral)	Pfizer	Approved	35
Aripiprazole	Bristol Myers Squibb	Phase 3	40
Aripiprazole + Risperidone/Quetiapine	Bristol Myers Squibb	Pre-clinical	26
Miricorlilant + Miricorlilant + Placebo	Corcept Therapeutics	Phase 2	32
Miricorilant + Fluvoxamine	Corcept Therapeutics	Phase 1	26
Miricorilant + Placebo	Corcept Therapeutics	Phase 2	32
Olanzapine + CORT118335 + Placebo	Corcept Therapeutics	Phase 1	26